Skip to main content
. 2019 Dec 21;21(1):94. doi: 10.3390/ijms21010094

Table 3.

Inhibitors of GSK3 with positive effect in human CDM1 and DM1 myoblasts.

GSK3 Inhibitor Effects on Human CDM1 and DM1 Myoblasts
BIO [49]
  • ◾

    Normalization of CUGBP1 myogenic downstream targets (LEF1, DCX, RBM45 and Col4A)
Tideglusib [50]
  • ◾

    Improvement of differentiation

  • ◾

    Reduction of the mutant DMPK mRNA in CDM1 and DM1 myoblasts

  • ◾

    Reduction of CUG foci

  • ◾

    Normalization of GSK3β

  • ◾

    Normalization of myogenic downstream target of CUGBP1, RBM45

  • ◾

    Improvement of splicing of MBNL1 downstream target, BIN1